Anti-CD47-Mediated Immune Protection is Impaired by Some Post Treatment Chemotherapeutics. BALB/c mice (n = 6 per group) were injected subcutaneously with 3 × 106 A20 cells and were treated with 50 μg of anti-CD47 on days 12 and 17. Select chemotherapeutic agents were injected intraperitoneally (i.p.) at different time points. (a) 40 mg/ kg of paclitaxel (PTX) was injected i.p. in a single dose on day 11 (one day before anti-CD47) or three doses on days 15, 18, and 21 (starting three days after anti-CD47; n = 7 pooled from two experiments). Tumor growth is reported as the mean tumor size ± standard error of the mean (SEM) over time (**p<0.01; unpaired Student’s t-test). (b) 60 mg/kg of cisplatin (CTX; n = 5 per group) was injected i.p. in a single dose on day 11 (one day before anti-CD47) or three doses on days 15, 18, and 21 (starting three days after anti-CD47). Tumor growth is reported as the mean tumor size ± SEM over time (**p<0.01; two-way analysis of variance). One representative experiment out of two independent experiments is depicted. (c, d) Treated mice (n = 7 per group) had tumors removed by surgery and were rechallenged with 1.5 × 107 A20 cells one week after surgery. Percentage of tumor-free mice is shown. (*p< 0.05; Mantel-Cox). One representative experiment out of two independent experiments is depicted.Reprinted by permission from Macmillan Publishers Ltd: Nat Med. 2015;21:1209-1215, copyright 2015.